Brolucizumab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 582 publications
Real-world retinal vasculitis events reported with FDA-approved intravitreal anti-VEGF and complement inhibitor agents: an analysis of FAERS data.
Journal: Retina (Philadelphia, Pa.)
Published: August 21, 2026
Community-Level Variation in On-Label Versus Off-Label Anti-VEGF Use and Medicare Part B Spending.
Journal: Retina (Philadelphia, Pa.)
Published: July 21, 2026
Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.
Journal: Ocular immunology and inflammation
Published: June 01, 2026
Comparison of Retinal Nonperfusion in Diabetic Macular Edema Treated with Brolucizumab Versus Aflibercept: A KINGFISHER Trial Analysis.
Journal: American journal of ophthalmology
Published: May 24, 2026
Comparison of Retinal Nonperfusion in Diabetic Macular Edema Treated With Brolucizumab Versus Aflibercept: A KINGFISHER Trial Analysis.
Journal: American journal of ophthalmology
Published: May 24, 2026
Intravitreal Brolucizumab for Diabetic Macular Edema: Outcomes in Treatment-Naive and Anti-VEGF-Switched Eyes over 48 Weeks.
Journal: Journal of clinical medicine
Published: May 07, 2026
Cost analysis of aflibercept 8 mg versus other anti-VEGF agents
Journal: Vestnik oftalmologii
Published: April 28, 2026
Rational design, expression and refolding of a novel bispecific antibody to simultaneously target VEGF-A and Ang-2 for inhibition of angiogenesis.
Journal: Journal of pharmaceutical sciences
Published: April 27, 2026
Last Updated: 09/26/2026